Rate My Professor Gabe Kwong

Dr. Kwong's research bridges synthetic immunity and medicine, developing in vivo biosensors for early cancer detection and immune cell programming technologies like protease-activated nanosensors and synthetic biomarkers for urinary monitoring. His lab engineers enhancements for CAR T cell therapies, including lipid nanoparticle delivery of synthetic antigens to sensitize solid tumors. Notable publications include “Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens” (Nature Cancer, 2025), “AND-gated protease-activated nanosensors for programmable detection of anti-tumour immunity” (Nature Nanotechnology, 2025), “In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles” (Science Advances, 2022), and “Synthetic Biomarkers: A 21st century path to early cancer detection” (Nature Reviews Cancer, 2021). Holding over 40 patents and co-founding two biotechnology companies, his contributions feature highly cited works in Nature Biotechnology, Nature Medicine, and Science Translational Medicine. Honors encompass the NIH Director’s New Innovator Award ($1.5 million, 2016), NIH Pioneer Award, Burroughs Wellcome Fund Career Award at the Scientific Interface, NIH Ruth L. Kirschstein National Research Service Award, Sigma Xi Best Faculty Paper Award (2020), and leadership of the $49.5 million ARPA-H Cancer and Organ Degradome Atlas project for multi-cancer early detection.